CAMP4 Therapeutics Corporation Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Amount
CAMP4 Therapeutics Corporation (CAMP) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Amount of $554.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-05.
Financial Statements › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther · last filed 2026-03-05
- CAMP4 Therapeutics Corporation effective income tax rate reconciliation, nondeductible expense, other, amount for fiscal 2025 was $554.00K, a 20.43% increase from fiscal 2024.
- CAMP4 Therapeutics Corporation effective income tax rate reconciliation, nondeductible expense, other, amount for fiscal 2024 was $460.00K.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Amount 12 month |
|---|---|
| 2025-12-31 | $554.00K 10-K · filed 2026-03-05 |
| 2024-12-31 | $460.00K 10-K · filed 2026-03-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |
| NATURES SUNSHINE PRODUCTS INC (NATR) | United States | $0.228B | 20.51 |